Classification of osteoarthritis phenotypes by metabolomics analysis

BMJ Open

Volumn 4, Issue 11, 2014, Pages

  Zhang, Weidong ^a   Likhodii, Sergei ^a   Zhang, Yuhua ^a   Aref Eshghi, Erfan ^a   Harper, Patricia E ^a   Randell, Edward ^a   Green, Roger ^a   Martin, Glynn ^a   Furey, Andrew ^a   Sun, Guang ^a   Rahman, Proton ^a   Zhai, Guangju ^a,b  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLCARNITINE; AMINO ACID; BIOGENIC AMINE; CARNITINE; GLYCEROPHOSPHOLIPID; HEXOSE; LYSOPHOSPHATIDYLCHOLINE; PHOSPHATIDYLCHOLINE; SPHINGOLIPID;

ADULT; AGED; ARTICLE; BODY MASS; COLLAGEN METABOLISM; COMORBIDITY; DISEASE CLASSIFICATION; FEMALE; HIP ARTHROPLASTY; HUMAN; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; METABOLOMICS; OSTEOARTHRITIS; PATIENT CODING; PHENOTYPE; SYNOVIAL FLUID; TOTAL KNEE REPLACEMENT; CANADA; METABOLISM; MIDDLE AGED; PROCEDURES;

AGED; CANADA; FEMALE; HUMANS; MALE; METABOLOMICS; MIDDLE AGED; OSTEOARTHRITIS; PHENOTYPE; SYNOVIAL FLUID;

EID: 84911886343     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-006286     Document Type: Article

References (38)

1. Castañeda S, Roman-Blas JA, Largo R, et al. Osteoarthritis: A progressive disease with changing phenotypes. Rheumatology (Oxford) 2014; 53: 1-3.
2. Herrero-Beaumont G, Roman-Blas JA, Castañeda S, et al. Primary osteoarthritis no longer primary: Three subsets with distinct etiological, clinical, and therapeutic characteristics. Semin Arthritis Rheum 2009; 39: 71-80.
3. Knoop J, van der Leeden M, Thorstensson CA, et al. Identification of phenotypes with different clinical outcomes in knee osteoarthritis: Data from the Osteoarthritis Initiative. Arthritis Care Res (Hoboken) 2011; 63: 1535-42.
4. Scanzello CR, Umoh E, Pessler F, et al. Local cytokine profiles in knee osteoarthritis: Elevated synovial fluid interleukin-15 differentiates early from end-stage disease. Osteoarthritis Cartilage 2009; 17: 1040-8.
5. Solovieva S, Kamarainen OP, Hirvonen A, et al. Association between interleukin 1 gene cluster polymorphisms and bilateral distal interphalangeal osteoarthritis. J Rheumatol 2009; 36: 1977-86.
6. MacGregor AJ, Li Q, Spector TD, et al. The genetic influence on radiographic osteoarthritis is site specific at the hand, hip and knee. Rheumatology (Oxford) 2009; 48: 277-80.
7. Haynes MK, Hume EL, Smith JB. Phenotypic characterization of inflammatory cells from osteoarthritic synovium and synovial fluids. Clin Immunol 2002; 105: 315-25.
8. Katz JD, Agrawal S, Velasquez M. Getting to the heart of the matter: Osteoarthritis takes its place as part of the metabolic syndrome. Curr Opin Rheumatol 2010; 22: 512-19.
9. Bijlsma JW, Berenbaum F, Lafeber FP. Osteoarthritis: An update with relevance for clinical practice. Lancet 2011; 377: 2115-26.
10. Zhuo Q, Yang W, Chen J, et al. Metabolic syndrome meets osteoarthritis. Nat Rev Rheumatol 2012; 8: 729-37.
11. Ludwig TE, McAllister JR, Lun V, et al. Diminished cartilage-lubricating ability of human osteoarthritic synovial fluid deficient in proteoglycan 4: Restoration through proteoglycan 4 supplementation. Arthritis Rheum 2012; 64: 3963-71.
12. Zhai G, Wang-Sattler R, Hart DJ, et al. Serum branched-chain amino acid to histidine ratio: A novel metabolomic biomarker of knee osteoarthritis. Ann Rheum Dis 2010; 69: 1227-31.
13. Warde N. Osteoarthritis: Identification of a metabolomic biomarker for knee OA. Nat Rev Rheumatol 2010; 6: 381.
14. U.S. Department of Health and Human Services FaDA, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM) (2001) Guidance for Industry. Bioanalytical Method Validation.
15. Aref-Eshghi E, Rahman P, Zhang H, et al. Attempt to replicate the published osteoarthritis-associated genetic variants in the Newfoundland & Labrador Population. J Orthop Rheumatol 2014; 1: 5-10.
16. Bartel J, Krumsiek J, Theis FJ. Statistical methods for the analysis of high-throughput metabolomics data. Comput Struct Biotechnol J 2013; 4: E201301009.
17. Lindon JC, Holmes E, Nicholson JK. Metabonomics techniques and applications to pharmaceutical research & development. Pharml Res 2006; 23: 1075-88.
18. Beckonert O, Bollard ME, Ebbles TMD, et al. NMR-based metabonomic toxicity classification: Hierarchical cluster analysis and k-nearest-neighbour approaches. Anal Chim Acta 2003; 490: 3-15.
19. Adams SB Jr, Setton LA, Nettles DL. The Role of Metabolomics in Osteoarthritis Research. J Am Acad Orthop Surg 2013; 21: 63-4.
20. Vaz FM, Wanders RJ. Carnitine biosynthesis in mammals. Biochem J 2002; 361: 417-29.
21. Gieger C, Geistlinger L, Altmaier E, et al. Genetics meets metabolomics: A genome-wide association study of metabolite profiles in human serum. PLoS Genet 2008; 4: E1000282.
22. Ramos-Roman MA, Sweetman L, Valdez MJ, et al. Postprandial changes in plasma acylcarnitine concentrations as markers of fatty acid flux in overweight and obesity. Metabolism 2012; 61: 202-12.
23. Zammit VA, Ramsay RR, Bonomini M, et al. Carnitine, mitochondrial function and therapy. Adv Drug Deliv Rev 2009; 61: 1353-62.
24. Kalim S, Clish CB, Wenger J, et al. A plasma long-chain acylcarnitine predicts cardiovascular mortality in incident dialysis patients. J Am Heart Assoc 2013; 2: E000542.
25. Murphy MG, Crocker JF, O'Regan P, et al. Carnitine, acylcarnitine and amino acid profiles analyzed by tandem mass spectrometry in a surfactant/virus mouse model of acute hepatic encephalopathy. Chemosphere 2007; 68: 1692-8.
26. Berridge MJ, Irvine RF. Inositol phosphates and cell signalling. Nature 1989; 341: 197-205.
27. Farooqui AA, Horrocks LA, Farooqui T. Glycerophospholipids in brain: Their metabolism, incorporation into membranes, functions, and involvement in neurological disorders. Chem Phys Lipids 2000; 106: 1-29.
28. Hills BA. Surface-active phospholipid: A Pandora's box of clinical applications. Part II. Barrier and lubricating properties. Intern Med J 2002; 32: 242-51.
29. Kosinska MK, Liebisch G, Lochnit G, et al. Sphingolipids in human synovial fluid-A lipidomic study. PLoS ONE 2014; 9: E91769.
30. Gerritsen ME, Shen CP, Perry CA. Synovial fibroblasts and the sphingomyelinase pathway: Sphingomyelin turnover and ceramide generation are not signaling mechanisms for the actions of tumor necrosis factor-alpha. Am J Pathol 1998; 152: 505-12.
31. Cutler RG, Mattson MP. Sphingomyelin and ceramide as regulators of development and lifespan. Mech Ageing Dev 2001; 122: 895-908.
32. Spiegel S, Milstien S. Sphingosine-1-phosphate: An enigmatic signalling lipid. Nat Rev Mol Cell Biol 2003; 4: 397-407.
33. Luberto C, Kraveka JM, Hannun YA. Ceramide regulation of apoptosis versus differentiation: A walk on a fine line. Lessons from neurobiology. Neurochem Res 2002; 27: 609-17.
34. McGregor NR, Dunstan RH, Zerbes M, et al. Preliminary determination of the association between symptom expression and urinary metabolites in subjects with chronic fatigue syndrome. Biochem Mol Med 1996; 58: 85-92.
35. Livshits G, Zhai G, Hart DJ, et al. Interleukin-6 is a significant predictor of radiographic knee osteoarthritis: The Chingford Study. Arthritis Rheum 2009; 60: 2037-45.
36. Kaddam IM, Iqbal SJ, Holland S, et al. Comparison of serum osteocalcin with total and bone specific alkaline phosphatase and urinary hydroxyproline: Creatinine ratio in patients with Paget's disease of bone. Ann Clin Biochem 1994; 3: 327-30.
37. Lippiello L, Hall D, Mankin HJ. Collagen synthesis in normal and osteoarthritic human cartilage. J Clin Invest 1977; 59: 593-600.
38. Liu Y, Chen T, Qiu Y, et al. An ultrasonication-assisted extraction and derivatization protocol for GC/TOFMS-based metabolite profiling. Anal Bioanal Chem 2011; 400: 1405-17.